Counterion-insulated near-infrared dyes in biodegradable polymer nanoparticles for <i>in vivo</i> imaging

Sobska, Joanna; Andreiuk, Bohdan; Aparin, Ilya O.; Reisch, Andreas; Krężel, Wojciech; Klymchenko, Andrey S.

doi:10.1039/d1na00649e

Cited by 14 publications

(5 citation statements)

References 48 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distribution of nanoparticles in mice was investigated using near-infrared in vivo imaging to evaluate the targeting of nanoparticles in vivo better 28 . NPs loaded with rhodamine-B (RDM) were prepared by replacing PTX with RDM.…”

Section: Methodsmentioning

confidence: 99%

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo

Ma¹,

Huang²,

Liu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Background: Improving the aggregation and penetration in tumor sites increases the anti-tumor efficacy of nanomedicine. In the current study, we designed cyclodextrin modified PLGA nanoparticles loaded with paclitaxel to elevate the accumulation and prolong circulation of chemotherapy drugs in vivo . Methods: The PLGA nanoparticles loaded with paclitaxel (PTX PLGA NPs) and cyclodextrin (CD) modified PLGA nanoparticles loaded with paclitaxel (PTX PLGA/CD NPs) were prepared using the emulsification solvent evaporation method. The nanoparticles were characterized by particle size, zeta potential, encapsulation efficiency, infrared spectroscopy analysis and X-Ray diffraction (XRD). Then, drug release of the nanoparticles was evaluated via reverse dialysis method in vitro . Finally, the in vivo distribution fate and pharmacokinetic characteristics of the nanoparticles were assessed in mice and rats. Results: The average particle size, zeta potential, and encapsulation efficiency of PTX PLGA NPs were (163.57±2.07) nm, - (20.53±2.79) mV and (60.44±6.80)%. The average particle size, zeta potential, and encapsulation efficiency of PTX PLGA/CD NPs were (148.57±1.66) nm, - (11.42±0.84) mV and (85.70±2.06)%. In vitro release studies showed that PTX PLGA/CD NPs were released more slowly compared to PTX PLGA NPs under normal blood pH conditions, while PTX PLGA/CD NPs were released more completely under tumor site pH conditions. The modified PLGA nanocarrier (PLGA/CD NPs) increased drug residence time and accumulation than the plain PLGA nanocarrier (PLGA NPs) in vivo distribution. In addition, the elimination half-life, area under the drug-time curve, and maximum blood concentration of the nanoparticle group were higher than those of Taxol ® , especially the PTX PLGA/CD NPs group, which was significantly different from Taxol ® and plain nanoparticle groups ( p <0.001). Conclusions: The 2-HP-β-CD modified PLGA nanoparticles prolonged circulation time and accumulation of the chemotherapy drug paclitaxel in vivo .

show abstract

Section: Methodsmentioning

confidence: 99%

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo

Ma¹,

Huang²,

Liu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

show abstract

“…[27,28] They can also be successfully employed for cancer treatment because of their high loading capacity of active ingredients. [29][30][31] Their compatibility with biomolecular and cellular systems and modulated degradability facilitate their circulation in the blood and the removal of the load after its release. For all these intriguing applications, the meticulous selection of nanoparticle composition and surface properties is fundamental to their end-application success.…”

Section: Introductionmentioning

confidence: 99%

Surface Bio‐engineered Polymeric Nanoparticles

Haidar,

Bilek,

Akhavan

2024

Small

View full text Add to dashboard Cite

Surface bio‐engineering of polymeric nanoparticles (PNPs) has emerged as a cornerstone in contemporary biomedical research, presenting a transformative avenue that can revolutionize diagnostics, therapies, and drug delivery systems. The approach involves integrating bioactive elements on the surfaces of PNPs, aiming to provide them with functionalities to enable precise, targeted, and favorable interactions with biological components within cellular environments. However, the full potential of surface bio‐engineered PNPs in biomedicine is hampered by obstacles, including precise control over surface modifications, stability in biological environments, and lasting targeted interactions with cells or tissues. Concerns like scalability, reproducibility, and long‐term safety also impede translation to clinical practice. In this review, these challenges in the context of recent breakthroughs in developing surface‐biofunctionalized PNPs for various applications, from biosensing and bioimaging to targeted delivery of therapeutics are discussed. Particular attention is given to bonding mechanisms that underlie the attachment of bioactive moieties to PNP surfaces. The stability and efficacy of surface‐bioengineered PNPs are critically reviewed in disease detection, diagnostics, and treatment, both in vitro and in vivo settings. Insights into existing challenges and limitations impeding progress are provided, and a forward‐looking discussion on the field's future is presented. The paper concludes with recommendations to accelerate the clinical translation of surface bio‐engineered PNPs.

show abstract

“…[ 64 ] Different dyes can be encapsulated to prepare NPs of any desired color, which was applied for multicolor barcoding of live cells and for long‐term tracking in vitro and in vivo. [ 65 ] Their functionalization with PEG [ 66 ] or zwitterionic [ 67 ] groups provides them with “stealth” properties with minimized nonspecific interactions. Moreover, zwitterionic groups stabilize NPs in physiological conditions.…”

Section: Introductionmentioning

confidence: 99%

Biotinylated Fluorescent Polymeric Nanoparticles for Enhanced Immunostaining

et al. 2023

Self Cite

View full text Add to dashboard Cite

The performance of fluorescence immunostaining is physically limited by the brightness of organic dyes, whereas fluorescence labeling with multiple dyes per antibody can lead to dye self-quenching. The present work reports a methodology of antibody labeling by biotinylated zwitterionic dye-loaded polymeric nanoparticles (NPs). A rationally designed hydrophobic polymer, poly(ethyl methacrylate) bearing charged, zwitterionic and biotin groups (PEMA-ZI-biotin), enables preparation of small (14 nm) and bright fluorescent biotinylated NPs loaded with large quantities of cationic rhodamine dye with bulky hydrophobic counterion (fluorinated tetraphenylborate). The biotin exposure at the particle surface is confirmed by Förster resonance energy transfer with dye-streptavidin conjugate. Single-particle microscopy validates specific binding to biotinylated surfaces, with particle brightness 21-fold higher than quantum dot-585 (QD-585) at 550 nm excitation. The nanoimmunostaining method, which couples biotinylated antibody (cetuximab) with bright biotinylated zwitterionic NPs through streptavidin, significantly improves fluorescence imaging of target epidermal growth factor receptors (EGFR) on the cell surface compared to a dye-based labeling. Importantly, cetuximab labeled with PEMA-ZI-biotin NPs can differentiate cells with distinct expression levels of EGFR cancer marker. The developed nanoprobes can greatly amplify the signal from labeled antibodies, and thus become a useful tool in the high-sensitivity detection of disease biomarkers.

show abstract

Counterion-insulated near-infrared dyes in biodegradable polymer nanoparticles for in vivo imaging

Abstract: Bulky hydrophobic counterions were applied for encapsulation of near-infrared cyanine dyes into biodegradable polymer matrix with minimized self-quenching, yielding fluorescent nanoparticles with stealth PEG shell for in vivo imaging.

Cited by 14 publications

References 48 publications

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo

Surface Bio‐engineered Polymeric Nanoparticles

Biotinylated Fluorescent Polymeric Nanoparticles for Enhanced Immunostaining

Contact Info

Product

Resources

About